Download PDF
Int J Sports Med 2000; 21(6): 406-411
DOI: 10.1055/s-2000-3834
Physiology and Biochemistry
Georg Thieme Verlag Stuttgart · New York

The Effect of Supraphysiological Doses of Anabolic Androgenic Steroids on Collagen Metabolism

M. Pärssinen1,2 ,  T. Karila1,2 ,  V. Kovanen3 ,  T. Seppälä1
  • 1 National Public Health Institute, Laboratory of Substance Abuse, Helsinki
  • 2 Institute of Biomedicine, Department of Pharmacology and Toxicology, University of Helsinki
  • 3 Department of Health Sciences, University of Jyväskylä, Finland
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

We examined the effect of supraphysiological doses of anabolic androgenic steroids (AAS) on collagen metabolism and whether the changes reflect the alterations in muscle, bone, and tendon collagen metabolism, possibly in a tissue-specific manner. Serum carboxyterminal propeptide of type I procollagen (PICP), carboxyterminal telopeptide of type I collagen (ICTP), aminoterminal propeptide of type III procollagen (PIIINP), urine hydroxylysylpyridinoline (HP), and lysylpyridinoline (LP) as well as urine creatinine were determined from 17 men abusing AAS. Measurements were made twice during the intake of AAS and twice during the subsequent withdrawal period. When the volunteers were on steroids, their serum PIIINP concentrations and urine HP/LP ratio were significantly higher and their serum ICTP concentrations were significantly lower than during the withdrawal period (p < 0.05). Serum PIIINP correlated with total cumulative doses of injectable intramuscular steroids, and serum ICTP correlated with the duration of the steroid intake period (p < 0.05). The results suggest that high doses of AAS decrease the degradation and seem to increase the synthesis of type I collagen. Furthermore, high doses of AAS are suggested to enhance soft tissue collagen metabolism on the basis of increased type III collagen synthesis and elevated HP/LP ratio during the steroid administration period. Although the tissue-specific turnover of collagen of soft connective tissues remains unknown, the turnover of bone collagen seems not to change following the use of high doses of AAS, at least within the time interval of the present study.

Key words:

Anabolic steroids, collagen, PICP, ICTP, PIIINP, glucocorticosteroids.

References

  • 1 Alén M, Reinilä M, Vihko R. Response of serum hormones to androgen administration in power athletes.  Med Sci Sports Exerc. 1985;  17 354-359
    PubMedGoogle Scholar
  • 2 Bach B R, Warren R F, Wickiewicz T L. Triceps rupture: a case report and literature review.  Am J Sports Med. 1987;  15 285-289
    PubMedGoogle Scholar
  • 3 Bhasin S, Storer T W, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell T J, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.  N Engl J Med. 1996;  335 1-7
    CrossrefPubMedGoogle Scholar
  • 4 Black D, Duncan A, Robins S P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography.  Anal Biochem. 1988;  167 197-203
    PubMedGoogle Scholar
  • 5 Bollen A-M, Martin M D, Leroux B G, Eyre D R. Circadian variation in urinary excretion on bone collagen cross-links.  J Bone Min Res. 1995;  10 1885-1890
    PubMedGoogle Scholar
  • 6 Cheng S, Kovanen V, Heikkinen E, Suominen H. Serum and urine markers of type I collagen metabolism in elderly women with high and low bone mineral density.  Eur J Clin Invest. 1996;  26 186-191
    CrossrefPubMedGoogle Scholar
  • 7 Donike M, Geyer H, Gotzmann A. 1988 Dope analysis. In: Bellotti P, Benzi G, Ljunqvist A (eds) Official proceedings of the international athletic foundation world symposium on doping in sport - 1987. London; International Athletic Foundation 1988: 53-80
    Google Scholar
  • 8 Eyre D R, Koob T J, Van Ness K P. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography.  Anal Biochem. 1984;  137 380-388
    CrossrefPubMedGoogle Scholar
  • 9 Eyre D R. The specificity of collagen cross-links as markers of bone and connective tissue degradation.  Acta Orthop Scand. 1995;  66 166-170
    PubMedGoogle Scholar
  • 10 Eyre D R. Biochemical basis of collagen metabolites as bone turnover markers. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of Bone Biology. San Diego; Academic Press 1996: 143-153
    Google Scholar
  • 11 Fujimoto D. Evidence for natural existence of pyridinoline crosslink in collagen.  Biochem Biophys Res Commun. 1980;  93 948-953
    CrossrefPubMedGoogle Scholar
  • 12 Haupt H A, Rovere G D. Anabolic steroids: A review of the literature.  Am J Sports Med. 1984;  12 469-484
    CrossrefPubMedGoogle Scholar
  • 13 Haupt H A. Anabolic steroids and growth hormone.  Am J Sports Med. 1993;  21 468-474
    PubMedGoogle Scholar
  • 14 Inhofe P D, Grana W A, Egle D, Min K-W, Tomasek J. The effects of anabolic steroids on rat tendon. An ultrastructural, biomechanical, and biochemical analysis.  Am J Sports Med. 1995;  23 227-232
    PubMedGoogle Scholar
  • 15 James I T, Walne A J, Perrett D. The measurement of pyridinium crosslinks: a methodological overview.  Ann Clin Biochem. 1996;  33 397-420
    PubMedGoogle Scholar
  • 16 Kramhøft M, Solgaard S. Spontaneous rupture of the extensor pollicis longus tendon after anabolic steroids.  J Hand Surg (Br). 1986;  11 87
    CrossrefPubMedGoogle Scholar
  • 17 Laseter J T, Russell J A. Anabolic steroid-induced tendon pathology: a review of the literature.  Med Sci Sports Exerc. 1991;  23 1-3
    PubMedGoogle Scholar
  • 18 Melkko J, Niemsi S, Risteli J. Radioimmunoassay for the carboxyterminal propeptide of human type I procollagen (RICP).  Clin Chem. 1990;  36 1328-1332
    PubMedGoogle Scholar
  • 19 Michna H. Organisation of collagen fibrils in tendon: changes induced by an anabolic steroid.  Virch Arch. 1986;  52 87-98
    PubMedGoogle Scholar
  • 20 Nieminen M S, Rämö M P, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M, Heikkilä J. Serious cardiovascular side-effects of large doses of anabolic steroids in weight lifters.  Eur Heart J. 1996;  17 1576-1583
    CrossrefPubMedGoogle Scholar
  • 21 Oikarinen A, Autio P, Vuori J, Väänänen K, Risteli L, Kiistala U, Risteli J. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen.  Br J Dermatol. 1992;  126 172-178
    PubMedGoogle Scholar
  • 22 Palokangas H, Kovanen V, Duncan A, Robins S P. Age-related changes in the concentration of hydroxypyridinium crosslinks in functionally different skeletal muscles.  Matrix - Coll Rel Res. 1992;  12 291-296
    PubMedGoogle Scholar
  • 23 Panteghini M, Pagani F. Biological variation in urinary excretion of pyridinium crosslinks: recommendations for the optimum specimen.  Ann Clin Biochem. 1996;  33 36-42
    PubMedGoogle Scholar
  • 24 Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowant A P, Risteli L. Rapid equilibrium radioimmunoassay for the aminoterminal propeptide of human type III procollagen.  Clin Chem. 1988;  34 715-718
    PubMedGoogle Scholar
  • 25 Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: A new serum marker for bone resorption.  Clin Chem. 1993;  39 635-640
    PubMedGoogle Scholar
  • 26 Rogol A D, Yesalis C E. Anabolic-androgenic steroids and athletes: What are the issues?.  J Clin Endoc Metab. 1992;  74 465-469
    PubMedGoogle Scholar
  • 27 Schlemmer A, Hassager C, Jensen S B, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women.  J Clin Endoc Metab. 1992;  74 476-480
    PubMedGoogle Scholar
  • 28 SYSTAT for Windows .Statistics, Version 5 Edition. Evanston, IL; SYSTAT Inc. 1992: 750
    Google Scholar
  • 29 Vanderschueren D, Bouillon R. Androgens and bone.  Calcif Tissue Int. 1995;  56 341-346
    CrossrefPubMedGoogle Scholar
  • 30 Yesalis C E, Wright J E, Bahrke M S. Epidemiological and policy issues in the measurements of the long term health effects of anabolic-androgenic steroids.  Sports Med. 1989;  8 129-138
    PubMedGoogle Scholar

Miia Pärssinen

National Public Health Institute Laboratory of Substance Abuse

Mannerheimintie 166 00300 Helsinki Finland

Phone: Phone:+ 358 (9) 47448425

Fax: Fax:+ 358 (9) 47448553

Email: E-mail:miia.parssinen@ktl.fi

      >